Panag Pharma Announces Health Canada License for a Topical Cold-Sore Formulation NPN 80084806
Halifax, Nova Scotia. Panag Pharma announces Health Canada approval for a topical Cold-Sore Formulation, a new generation topical formulation with a dual mechanism of action that improves healing rates and reduces symptoms, i.e. pain, associated with herpes labialis (cold sores). The topical Cold-Sore Formulation is a natural health product indicated for the relief of symptoms associated with cold sores/oral herpes.
Topical Cold-Sore product uses a novel technology that combines the known benefits of zinc, reducing viral loads and improving healing rates, and also targets the endocannabinoid system and TRPV1 receptors, both known to play a key role in modulation of pain. There is no other similar product on the market. Panag Pharma will move forward with a regional launch of the topical Cold-Sore Formulation in 2018.
About Panag Pharma Inc.
Panag Pharma is a Halifax, Nova Scotia based Life Sciences company developing a range of products which provide relief from chronic pain and inflammation, especially in sensitive sites, using proprietary plant-derived compounds.